When it comes to developing artificial intelligence policy, the US Food and Drug Administration has a broad base of staff expertise to use.
Key Takeaways
-
The FDA has a wide variety of AI expertise to help develop policy.
That fact was evident during a recent FDA/Clinical Trials Transformation Initiative meeting on AI in drug and biological product development....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?